Treatment of hepatitis C in liver transplant recipients

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 126-135

  Gordon, Fredric D ^a   Kwo, Paul ^b   Vargas, Hugo E ^c  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS C ANTIBODY; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ANEMIA; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY VIROLOGIC RESPONSE; ERADICATION THERAPY; GRAFT RECIPIENT; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MICROBIOLOGICAL PARAMETERS; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RAPID VIROLOGIC RESPONSE; RECURRENT VIRUS INFECTION; REVIEW; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN;

EID: 67649219694     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21694     Document Type: Review

References (62)

1. World Health Organization. Hepatitis C: fact sheet no. 164. Revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/ fs164/en. Accessed October 2008.
2. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107:10S-15S.
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
4. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(suppl 1):S74-S83.
5. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(suppl 1):S30-S34.
6. Health Resources and Services Administration. 2006 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005. Rockville, MD: Healthcare Systems Bureau; 2008.
7. Kim WR, Benson JT, Hindman A, Brosgart C, Fortner-Burton C. Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US [abstract]. Hepatology 2007;46(suppl 1):238A.
8. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
9. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
10. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29: 1220-1226.
11. Wiesner RH, Sorrell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9(suppl 3):S1-S9.
12. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002;8:10-20.
13. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000;13: 229-237.
14. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8(suppl 1):S14-S18.
15. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007;13:719-724.
16. Saab S, Niho H, Comulada S, Hiatt J, Durazo F, Han S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005;25:940-945.
17. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
18. Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, Marino IR. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998;65:82-86.
19. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41:289-298.
20. Nair S, Eason J, Loss G. Early treatment of recurrent hepatitis C in liver transplant recipients: is the virological and histological response better [abstract]? Gastroenterology 2002;122(suppl 1):204A.
21. Mazzaferro V, Schiavo M, Caccamo L. Prospective randomized trial on early treatment of HCV infection after liver transplantation in HCV-RNA positive patients [abstract]. Liver Transpl 2003;9:141A.
22. Reddy R, Fried M, Dickson R. Interferon alfa-2b and ribavirin vs. placebo in early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicenter randomized trial [abstract]. Gastroenterology 2002;122(suppl 1):632A.
23. Bzowej NH, Nelson D, Thommes JA, Hamzeh FM, Charlton M. A Randomized controlled trial of prophylactically administered peginterferon alfa-2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation (OLT) for hepatitis C: a report of initial safety and tolerability [abstract]. Hepatology 2006;44(suppl 1):188A.
24. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5:118-124.
25. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
26. Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12:1805-1812.
27. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007;13:1100-1108.
28. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
29. Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, et al. Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-59.
30. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon g2b and ribavirin: an open-label series. Transplantation 2004;77:190-194.
31. Ross AS, Bhan AK, Pascual M, Thiim M, Cosimi AB, Chung RT. Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004;18:166-173.
32. Mukherjee S, Lyden E. Impact of pegylated interferon α-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006;26:529-535.
33. Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007;7:448-453.
34. Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-1307.
35. Rahim N, Prosser C, Bowlus C, Török N, Troppmann C, Ramsamooj R, et al. Increasing adherence to therapy for recurrent hepatitis C after liver transplantation by starting at lower drug doses and adding growth factors. Practical Gastroenterol 2007;31:24-33.
36. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: ontreatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53-58.
37. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-287.
38. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005;5:1909-1913.
39. Lilly L, Selzner N, Therapondos G, Renner EL, Selzner M, McGilvray I, et al. Improved survival in liver transplant recipients (LT) treated for recurrent hepatitis C (HCV) is seen in both relapsers and in sustained responders. Paper presented at: 2008 American Transplant Congress; May 31-June 4, 2008; Toronto, Canada.
40. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
41. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
42. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
43. Mukherjee S, Rogge J, Weaver LK, Schafer DF. De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation. Transplant Proc 2004;36:1494-1497.
44. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12:827-830.
45. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009-1017.
46. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995;8:61-64.
47. Calmus Y, Duvoux C, Pageaux GP, Messner M, Wolf P, Rostaing L, et al. Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: final report. Paper presented at: 2008 American Transplant Congress; May 31-June 4, 2008; Toronto, Canada.
48. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
49. Cescon M, Grazi GL, Cucchetti A, Ravaioli M, Ercolani G, Vivarelli M, et al. Viral genotype, immunosuppression with cyclosporine and donor age predict sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Paper presented at: 2008 American Transplant Congress; May 31-June 4, 2008; Toronto, Canada.
50. Verna EC, Pichardo EM, Emond JC, Brown RS Jr. Low dose slowly tapered steroids for immunosuppression in hepatitis C virus infected liver transplant recipients. Paper presented at: 2008 American Transplant Congress; May 31-June 4, 2008; Toronto, Canada.
51. Klintmalm GB, Fasola CG, Jennings L, Heffron TG, Sher L, Mulligan D, et al. Hepatitis C (HCV)-3 study: benefits of a steroid-free immunosuppression (IS) regimen in HCV-infected liver transplant recipients (OLT) may become evident only after long-term follow up. Paper presented at: 2008 American Transplant Congress; May 31-June 4, 2008; Toronto, Canada.
52. Shiffman ML. Factors contributing to failure when treating patients with chronic hepatitis C virus infection. Gastroenterol Hepatol 2007;3(suppl 20):4-11.
53. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
54. Alkofer B, Samstein B, Guarrera JV, Kin C, Jan D, Bellemare S, et al. Extended-donor criteria liver allografts. Semin Liver Dis 2006;26:221-233.
55. Foster R, Zimmerman M, Trotter JF. Expanding donor options: marginal, living, and split donors. Clin Liver Dis 2007;11:417-429.
56. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez- Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236.
57. Charlton MR, Bzowej N, Rossi S, Nelson DR. Prophylactic peginterferon alfa-2a/ribavirin vs no prophylaxis following orthotopic liver transplantation (OLT) for hepatitis C: 24-week virologic and safety responses [abstract]. Hepatology 2007;46(suppl):244A.
58. Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 2006;12:1317-1319.
59. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
60. Féray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reyne's M, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998;128:810-816.
61. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12: 1381-1389.
62. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941-949.